Sanofi (NYSE: SNY) reported earnings on April 27. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended March 31 (Q1), Sanofi met expectations on revenues and beat expectations on earnings per share.

Compared to the prior-year quarter, revenue improved slightly and GAAP earnings per share expanded significantly.

Gross margins contracted, operating margins improved, and net margins improved.

Revenue details
Sanofi logged revenue of $11.35 billion. The 12 analysts polled by S&P Capital IQ foresaw revenue of $11.48 billion on the same basis. GAAP reported sales were 2.5% higher than the prior-year quarter's $11.62 billion.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
EPS came in at $2.47. The eight earnings estimates compiled by S&P Capital IQ averaged $2.23 per share. GAAP EPS of $1.84 for Q1 were 39% higher than the prior-year quarter's $1.32 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
For the quarter, gross margin was 70.6%, 50 basis points worse than the prior-year quarter. Operating margin was 26.0%, 20 basis points better than the prior-year quarter. Net margin was 20.4%, 550 basis points better than the prior-year quarter.

Looking ahead
Next quarter's average estimate for revenue is $11.52 billion. On the bottom line, the average EPS estimate is $1.90.

Next year's average estimate for revenue is $45.86 billion. The average EPS estimate is $7.71.

Investor sentiment
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Sanofi is outperform, with an average price target of $81.64.

Can your portfolio provide you with enough income to last through retirement? You'll need more than Sanofi. Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks." Click here for instant access to this free report.